Immunogenicity of biologic agents

Biologics have become a core component of many treatment strategies for rheumatic inflammation. Scientists often consider that immunogenicity is the important limiting factor in the early stages of development of biological agents. However, theoretical guidance is relatively limited and the determination methods for measuring immunogenicity are complex, making the development of past research difficult. But now, the emergence of biosimilars has sparked new interest in immunogenicity, the development of more accurate and convenient testing methods, a greater understanding of the pharmacokinetic results of immunogenicity, and comprehensive and specific guidelines from regulators. Rheumatologists’ overall understanding of the field has greatly improved, including the factors that cause the immunogenicity, the potential clinical consequences, and the impact on daily treatment.

All biological agents are immunogenic and many pathways affect their bioavailability, including patient-specific factors, disease-specific characteristics, and genetic background.

Factors affecting the immunogenicity of biological agents:

Target antigen:

solubility

Whether it binds to the cell

Biological agent molecules:

Sequence: mouse or human sequence

Sexual dimorphism

Structure: glycosylation or other post-translational modifications

Biological products:

preparation

dose

Delivery way

Dosing frequency

Aggregates and impurities

Patient:

Disease types

Disease activity

Concomitant therapy

Genetic factors

In theory, humanized antibodies should have lower immunogenicity than chimeric antibodies because there are fewer non-human protein sequences in the variable region that might be considered foreign. Infliximab (the only chimeric monoclonal antibody among the five available TNF inhibitors) is more immunogenic than the other four TNF inhibitors. The debate over the immunogenicity of chimeric, humanized, and fully humanized antibodies has been going on for a long time, and the data reviewed in this paper suggest that the immunogenicity of fully humanized antibodies may be the lowest. See the table below:

Frequency of anti-drug antibody formation in rheumatic diseases

The detection and evaluation of ADAs is a complex process and the results may be influenced by the analytical methods used. Therefore, it is important to use specific and approved strategies when evaluating immune responses. The screening test must be sensitive, specific, and able to identify all ADAs subtypes of a given biologic agent. Immunogenicity was assessed by different types of immunoassays, such as enzyme-linked immunosorption assays (ELISAs), electrochemical luminescence immunoassays (ECLIAs), and radioimmunoassays, as well as by different forms of immunoassays, such as direct, indirect, bridging, and competitive forms. The chart below shows the commonly used forms of immunoassay for anti-drug antibody (ADA) tests and their advantages and disadvantages.

commonly used forms of immunoassay for anti-drug antibody (ADA) tests and their advantages and disadvantages

Reference：

Strand, V., Goncalves, J. & Isaacs, J.D. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol 17, 81–97 (2021). https://doi.org/10.1038/s41584-020-00540-8

Contact Us

Email : marketing@medicilon.com

Tel : +86 021 58591500

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Enzyme Activity Assay Service

Enzymatic assay Lance Assay Alphascreen Assay Z’-LYTE Assay Adapta Assay Kinase-Glo Assay ADP-Glo Assay Ligand Binding Assay ELISA Assay HTRF Assay Enzyme activity assays are laboratory methods for measuring enzymatic activity. They are vital for the study of enzyme kinetics and enzyme inhibition. Enzyme units : Amounts of enzymes can either be expressed as molar amounts, as with any other chemical, or measured in terms of activity, in enzyme units. Medicilon provides various enzyme activity assays for kinases , phosphatases, proteinases, deacetylase, peptidase, esterase, and other enzymes. Our line of well-characterized immunoassays and biochemical kits ensures accurate and reproducible results. Enzyme is a large category of bio-molecules that catalyze various biological processes including metabolic processes, cellular signaling and regulation, cell division and apoptosis. Enzymatic reactions convert substrate molecules into chemically modified molecules products with high sp

阅读全文

Shanghai Medicilon Inc.

搜索此博客